American Academy of Pediatrics issues first childhood obesity guideline, backing weight-loss drugs for teens 12 and up
The guideline asks pediatricians to treat obesity as a chronic disease and makes medication an option for teenagers 12 and older, while noting it should not be used alone.
In January 2023, the American Academy of Pediatrics issued its first clinical practice guideline for evaluating and treating obesity in children and adolescents, and it includes a recommendation that providers offer weight-loss medication to teenagers 12 and older with obesity [1][2].
The guideline was published in the journal Pediatrics in the February 2023 issue, volume 151, issue 2, and is listed as a practice guideline in PubMed [1][2]. A 2023 commentary described it as the academy's first guidance on childhood obesity [2].
The medication recommendation is Key Action Statement 12. It says providers should offer weight loss pharmacotherapy to adolescents aged 12 and older with obesity as an adjunct to health behavior and lifestyle treatment [1]. For children aged 8 through 11, the guideline makes a weaker consensus recommendation [1]. The guideline states that no evidence supports medication as monotherapy — that is, medication on its own, without behavior and lifestyle treatment [1].
The rest of the document covers evaluation, diagnosis and treatment. It frames obesity as a chronic disease and describes intensive health behavior and lifestyle treatment and motivational interviewing [1]. It also includes sections on health equity, racism, weight bias and stigma, adverse childhood experiences, and disordered eating [1]. Body mass index is used for screening and diagnosis [1].
Separately, a statement of correction for the guideline was published in Pediatrics on January 1, 2024, in volume 153, issue 1 [2]. The PubMed record for that notice does not describe which parts of the guideline were changed [2].
Why it matters for patients
The guideline changes what families can expect from a pediatric visit. Obesity is framed as a chronic disease rather than a behavior problem, and for the first time the academy tells providers that medication is one of the tools available for teenagers 12 and older [1][2]. That means a parent or a 12-year-old may hear weight-loss medication discussed in the exam room, not just diet and exercise [1].
The age cutoff means the recommendation is not uniform. For adolescents 12 and older, the guideline directs providers to offer pharmacotherapy; for children 8 through 11, it uses a weaker consensus recommendation, which reflects less agreement among the authors rather than a clear endorsement [1].
Medication is positioned as an addition to behavior and lifestyle treatment, not a substitute. The guideline says there is no evidence for using medication alone [1].
Several practical questions are not answered in the guideline's medication statement. Which specific drugs are covered, what doses should be used, how long treatment should last, and whether insurers will pay for it have not been disclosed [1]. The same is true of how the weaker recommendation for children 8 through 11 should be applied in practice [1].
Because a correction notice was issued in January 2024 [2], families and clinicians comparing versions of the document should check the date on whichever version they are reading.
What happens next
The guideline has no scheduled update listed in the publication record [1]. The January 1, 2024 correction statement stands as the most recent published change to the document [2]; what it corrected has not been described in the PubMed record for the notice [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.